Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Crispr Therapeutics AG and increased the price target to $80.00 from $65.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s promising developments in the field of cardiovascular care. The company’s CTX310 treatment has shown unprecedented results in reducing LDL and triglycerides by up to 87% and 84%, respectively, with just a single infusion. This positions CTX310 as a potential game-changer in lipid management, offering a comprehensive treatment for severe dyslipidemia that could replace lifelong therapies.
Additionally, the safety profile of CTX310 supports its potential as a low-risk, one-time treatment option. Despite some serious adverse events and a death occurring in the trial, these were unrelated to the treatment, and the overall safety remains favorable. The dual lipid-lowering benefits of CTX310, combined with its one-time infusion advantage, provide a competitive edge over existing therapies, making it an attractive option for both patients and investors. Kapoor maintains a 12-month price target of $80, indicating significant upside potential as more data becomes available.
In another report released today, Needham also reiterated a Buy rating on the stock with a $81.00 price target.